S Stintzing

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. doi request reprint Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group
    Nicolas Moosmann
    University of Munich, Klinikum Muenchen Grosshadern, Germany
    J Clin Oncol 29:1050-8. 2011
  2. doi request reprint FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
    Sebastian Stintzing
    Department of Hematology and Oncology, University of Munich, Munich, Germany DKTK, German Cancer Consortium, German Cancer Research Centre DKFZ, Heidelberg, Germany Electronic address
    Lancet Oncol 17:1426-1434. 2016
  3. pmc Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer
    Sebastian Stintzing
    USC Norris Comprehensive Cancer Center, Keck School of Medicine, Sharon Carpenter Laboatory, Los Angeles, California Department for Medical Oncology and Comprehensive Cancer Center, University of Munich, Munich, Germany
    Mol Cancer Ther 14:2374-81. 2015
  4. doi request reprint Sym004: Truly a New Level of Anti-EGFR Treatment?
    Sebastian Stintzing
    Department of Hematology and Oncology, Klinikum der Universitat Munchen, Munich, Germany
    Cancer Discov 5:578-80. 2015
  5. doi request reprint Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels
    Sebastian Stintzing
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    Anticancer Drugs 24:969-74. 2013
  6. doi request reprint Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases
    Sebastian Stintzing
    Department of Medical Oncology and Comprehensive Cancer Center, Klinikum Grosshadern, LMU, Munich, Germany
    Acta Oncol 52:971-7. 2013
  7. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
  8. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
  9. doi request reprint Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis
    Sebastian Stintzing
    Department of Medicine III, University Hospital Grosshadern, LMU Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Virchows Arch 455:171-85. 2009
  10. doi request reprint Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients
    S Stintzing
    Department of Hematology and Oncology, University Hospital Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Eur J Cancer 46:1026-32. 2010

Collaborators

Detail Information

Publications31

  1. doi request reprint Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group
    Nicolas Moosmann
    University of Munich, Klinikum Muenchen Grosshadern, Germany
    J Clin Oncol 29:1050-8. 2011
    ....
  2. doi request reprint FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
    Sebastian Stintzing
    Department of Hematology and Oncology, University of Munich, Munich, Germany DKTK, German Cancer Consortium, German Cancer Research Centre DKFZ, Heidelberg, Germany Electronic address
    Lancet Oncol 17:1426-1434. 2016
    ....
  3. pmc Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer
    Sebastian Stintzing
    USC Norris Comprehensive Cancer Center, Keck School of Medicine, Sharon Carpenter Laboatory, Los Angeles, California Department for Medical Oncology and Comprehensive Cancer Center, University of Munich, Munich, Germany
    Mol Cancer Ther 14:2374-81. 2015
    ..This is the first report suggesting that germline polymorphisms in the degradation process predict efficacy of cetuximab in patients with mCRC. Genes involved in EGFR turnover may be new targets in the treatment of mCRC...
  4. doi request reprint Sym004: Truly a New Level of Anti-EGFR Treatment?
    Sebastian Stintzing
    Department of Hematology and Oncology, Klinikum der Universitat Munchen, Munich, Germany
    Cancer Discov 5:578-80. 2015
    ..Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. Preclinical data suggest efficacy in anti-EGFR-resistant tumors, but it remains unclear whether a higher toxicity is outweighed by those advantages...
  5. doi request reprint Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels
    Sebastian Stintzing
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    Anticancer Drugs 24:969-74. 2013
    ..In mCRC patients treated with cetuximab, day-14 magnesium serum levels correlated with treatment efficacy...
  6. doi request reprint Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases
    Sebastian Stintzing
    Department of Medical Oncology and Comprehensive Cancer Center, Klinikum Grosshadern, LMU, Munich, Germany
    Acta Oncol 52:971-7. 2013
    ..In this analysis, two local therapies: 1) single session robotic radiosurgery (RRS) and 2) percutaneous radiofrequency ablation (RFA) were compared in a total of 60 heavily pretreated colorectal cancer patients...
  7. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
    ..This effect of Cet-ST is independent of the KRAS mutation status, suggesting that Cet-ST rather relates to constitutional factors of the patient than alterations of the EGFR pathway in the tumour...
  8. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
    ..The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies...
  9. doi request reprint Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis
    Sebastian Stintzing
    Department of Medicine III, University Hospital Grosshadern, LMU Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Virchows Arch 455:171-85. 2009
    ....
  10. doi request reprint Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients
    S Stintzing
    Department of Hematology and Oncology, University Hospital Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Eur J Cancer 46:1026-32. 2010
    ..Less invasive techniques have been invented to enhance local disease control. We investigated in a selected patient cohort local control of liver metastasis from CRC using robotic radiosurgery...
  11. ncbi request reprint Role of cannabinoid receptors and RAGE in inflammatory bowel disease
    Sebastian Stintzing
    Department of Medicine III, University Hospital Grosshadern, Marchioninistrasse 15, Munich, Germany
    Histol Histopathol 26:735-45. 2011
    ....
  12. doi request reprint Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors
    Sebastian Stintzing
    Department of Hematology and Oncology, University Hospital Grosshadern, LMU Munich, Munich, Germany
    Ann Surg Oncol 17:2877-83. 2010
    ..Here we present the therapeutic efficacy of a robotic radiosurgery for local control of liver metastases from solid tumors...
  13. doi request reprint Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group
    C Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Munich
    Ann Oncol 24:3051-5. 2013
    ..Prognostic factors associated with 60-day mortality would be helpful to identify high-risk patients in advance...
  14. pmc Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial
    C Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Br J Cancer 109:1428-36. 2013
    ..Liver-limited disease (LLD) denotes a specific subgroup of metastatic colorectal cancer (mCRC) patients...
  15. doi request reprint FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
    S Stintzing
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    Ann Oncol 23:1693-9. 2012
    ..In October 2008, an amendment terminated the inclusion of patients with KRAS-mutated tumours. This subgroup of patients is evaluated in the present analysis, while the study is ongoing for patients with KRAS wild-type tumours...
  16. ncbi request reprint FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306
    S Stintzing
    Medical Department III, Klinikum Grosshadern, University of Munich, Munich, Germany Department of Pathology, University of Munich, Munich, Germany Department of Oncology, Gesundheitszentrum St Marien GmbH, Amberg, Germany Onkologie Ravensburg, Muenster, Germany Practice for Medical Oncology, Landshut, Germany Krankenhaus Nordwest, Frankfurt, Germany Staedtische Kliniken Neuss Lukaskrankenhaus GmbH, Medical Department II, Neuss, Germany Klinikum Bayreuth GmbH, Bayreuth, Germany University of Munich Klinikum Grosshadern, Medical Department III, Munich, Germany Medical University of Vienna, Vienna, Austria Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
    J Clin Oncol 29:3575. 2011
    ..Until September 2008, patients (pts) without knowledge of their KRAS mutational status had been enrolled. Here, results of the subgroup of pts with mCRC carrying a mutated KRAS gene are presented...
  17. pmc Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer
    A Sebio
    Sharon A Carpenter Laboratory, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Pharmacogenomics J 16:312-9. 2016
    ..These promising results reveal polymorphisms in the Hippo pathway as biomarkers for stages II and III colon cancer.The Pharmacogenomics Journal advance online publication, 15 September 2015; doi:10.1038/tpj.2015.64. ..
  18. doi request reprint Genetic variants associated with colorectal brain metastases susceptibility and survival
    S Stremitzer
    Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Pharmacogenomics J . 2015
    ..The Pharmacogenomics Journal advance online publication, 22 December 2015; doi:10.1038/tpj.2015.86...
  19. doi request reprint KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
    D P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 139:953-61. 2013
    ..To investigate the impact of different KRAS mutations on treatment with the tyrosine kinase inhibitor sunitinib in SW48 colorectal cancer cell line variants...
  20. pmc Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
    D P Modest
    Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universitat, Munich German Cancer Consortium DKTK, German Cancer Research Centre DKFZ, Heidelberg
    Ann Oncol 27:1746-53. 2016
    ..To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy...
  21. ncbi request reprint Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial
    V Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany Department of Oncology, Gesundheitszentrum St Marien GmbH, Amberg, Germany Practice for Medical Oncology, Landshut, Germany Outpatient Department, Kronach, Germany Marienhospital, Stuttgart, Germany Privatklinik Schindlbeck, Herrsching, Germany Medical Department II, Klinikum Augsburg, Augsburg, Germany Department of Internal Medicine IV, Klinikum Bayreuth, Bayreuth, Germany Schlossbergklinik, Oberstaufen, Germany Onkologie Ravensburg, Muenster, Germany Ambulante Onkologie Zittau, Zittau, Germany Oncological Practice, Elisenhof, Munich, Germany Kliniken der Stadt und des Landkreises Rosenheim GmbH, Rosenheim, Germany Oncological Practice, MediCenter, Starnberg, Germany Oncological Practice, South Australia
    J Clin Oncol 29:3589. 2011
    ..Treatment related skin toxicity was evaluated separately for capecitabine and cetuximab. The present analysis investigates the correlation of capecitabine-attributed skin toxicity (Cape-ST) and parameters of treatment efficacy...
  22. doi request reprint Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
    Y Sunakawa
    Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Pharmacogenomics J . 2016
    ..Genetic predisposition of the host in the immunomodulators may serve as a prognostic biomarker in patients with locoregional GC.The Pharmacogenomics Journal advance online publication, 31 May 2016; doi:10.1038/tpj.2016.46...
  23. pmc Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
    J C von Einem
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 140:1607-14. 2014
    ..This analysis investigated the impact of primary tumor location on outcome of patients...
  24. doi request reprint Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)
    D P Modest
    Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Munich, Germany
    Int J Cancer . 2016
    ..Early response parameters may serve as stratification factors in trials recruiting pretreated patients. This article is protected by copyright. All rights reserved...
  25. doi request reprint CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy
    S Matsusaka
    Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Pharmacogenomics J . 2016
    ..The Pharmacogenomics Journal advance online publication, 9 August 2016; doi:10.1038/tpj.2016.59...
  26. doi request reprint Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)
    A Stähler
    Department of Medicine III And Comprehensive Cancer Centre, University Hospital Grosshadern, University of Munich, Germany
    Int J Cancer 138:739-46. 2016
    ..EREG expression appears as an independent prognostic marker in patients with mCRC receiving first-line irinotecan-based chemotherapy...
  27. pmc Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
    S Stintzing
    Medical Department III, University of Munich, Klinikum Muenchen Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Br J Cancer 105:206-11. 2011
    ..Treatment-related skin toxicity (ST) was evaluated separately for capecitabine and cetuximab. The present analysis investigates the correlation of capecitabine-attributed ST (Cape-ST) and parameters of treatment efficacy...
  28. ncbi request reprint Robotic radiosurgery of liver metastases of solid tumors
    S Stintzing
    University of Munich Klinikum Grosshadern, Munich, Germany University of Munich Klinikum Grosshdern, Munich, Germany European Cyberknife Center, Munich, Germany
    J Clin Oncol 27:e15049. 2009
    ..We here report the therapeutic efficacy of a robotic radiosurgery device for local control of liver metastases of solid tumors...
  29. doi request reprint A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
    A Sebio
    Division of Medical Oncology, Sharon A Carpenter Laboratory, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Pharmacogenomics J . 2016
    ..Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy.The Pharmacogenomics Journal advance online publication, 4 October 2016; doi:10.1038/tpj.2016.69...
  30. doi request reprint The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial
    D P Modest
    Department of Medicine III, University of Munich, Munich, Germany
    Int J Cancer 131:980-6. 2012
    ....
  31. pmc Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
    Y Sunakawa
    Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA Division of Medical Oncology, Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan
    Ann Oncol 26:2450-6. 2015
    ..We therefore hypothesized that variations in genes involved in regulating TAMs may predict clinical outcomes of bevacizumab treatment in patients with metastatic colorectal cancer (mCRC)...